US 11,925,648 B2
Solid dosage form having excellent stability
Naoya Mizutani, Hyogo (JP); Masayuki Morimoto, Hyogo (JP); Maki Okabe, Osaka (JP); Masaaki Ito, Hyogo (JP); and Go Kimura, Hyogo (JP)
Assigned to SHIONOGI & CO., LTD., Osaka (JP)
Filed by Shionogi & Co., Ltd., Osaka (JP)
Filed on Oct. 22, 2020, as Appl. No. 17/077,606.
Application 17/077,606 is a continuation of application No. PCT/JP2019/017146, filed on Apr. 23, 2019.
Claims priority of application No. 2018-083006 (JP), filed on Apr. 24, 2018.
Prior Publication US 2021/0106589 A1, Apr. 15, 2021
Int. Cl. A61K 31/5383 (2006.01); A61K 9/16 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/5383 (2013.01) [A61K 9/1611 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01)] 22 Claims
 
1. A solid dosage form comprising a compound represented by formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and an alkali metal chloride,
wherein the solid dosage form is in the form of a granule.